| MeSH term | MeSH ID | Detail |
|---|---|---|
| Breast Neoplasms | D001943 | 24 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Kolodych S et al. | Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates. | 2017 | Eur J Med Chem | pmid:28818506 |
| Cruz-Monserrate Z et al. | Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography. | 2003 | Eur. J. Biochem. | pmid:12950266 |
| Thery JC et al. | Resistance to human epidermal growth factor receptor type 2-targeted therapies. | 2014 | Eur. J. Cancer | pmid:24462377 |
| Schatten G and Schatten H | Effects of motility inhibitors during sea urchin fertilization: microfilament inhibitors prevent sperm incorporation and restructuring of fertilized egg cortex, whereas microtubule inhibitors prevent pronuclear migrations. | 1981 | Exp. Cell Res. | pmid:7308293 |
| Schrek R and Stefani SS | Toxicity of microtubular drugs to leukemic lymphocytes. | 1981 | Exp. Mol. Pathol. | pmid:7238845 |
| Suwanborirux K et al. | Ansamitocin P-3, a maytansinoid, from Claopodium crispifolium and Anomodon attenuatus or associated actinomycetes. | 1990 | Experientia | pmid:2298279 |
| Van den Mooter T et al. | Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. | 2015 | Expert Opin Biol Ther | pmid:25865453 |
| Dirix LY et al. | Trastuzumab emtansine in breast cancer. | 2013 | Expert Opin Biol Ther | pmid:23477731 |
| Bergamini A et al. | Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer. | 2016 | Expert Opin Investig Drugs | pmid:27797594 |
| Higa GM et al. | Biological considerations and clinical applications of new HER2-targeted agents. | 2010 | Expert Rev Anticancer Ther | pmid:20836684 |
| Cho WC and Roukos DH | Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets. | 2013 | Expert Rev Anticancer Ther | pmid:23259420 |
| Sapra P et al. | Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates. | 2013 | Expert Rev Clin Pharmacol | pmid:23978126 |
| Miranda Romero P and MarÃn Gil R | Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report. | 2015 | Farm Hosp | pmid:26005893 |
| Bhattacharyya B and Wolff J | Maytansine binding to the vinblastine sites of tubulin. | 1977 | FEBS Lett. | pmid:852577 |
| Yap LW et al. | Role of CD56 in Normal Kidney Development and Wilms Tumorigenesis. | 2017 | Fetal Pediatr Pathol | pmid:27935326 |
| Eckelmann D et al. | Spatial profiling of maytansine during the germination process of Maytenus senegalensis seeds. | 2017 | Fitoterapia | pmid:28385670 |
| Eckelmann D et al. | Occurrence and spatial distribution of maytansinoids in Putterlickia pyracantha, an unexplored resource of anticancer compounds. | 2016 | Fitoterapia | pmid:27521896 |
| Berdeja JG | Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma. | 2014 | Front Biosci (Landmark Ed) | pmid:24389179 |
| Lianos GD and Roukos DH | From linear 'dogma' and trastuzumab-emtansine to future transcriptional circuitry-based drug discovery for breast cancer. | 2014 | Future Oncol | pmid:24490597 |
| Moore KN et al. | FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. | 2018 | Future Oncol | pmid:29424243 |
| Doroshow DB and LoRusso PM | Trastuzumab emtansine: determining its role in management of HER2+ breast cancer. | 2018 | Future Oncol | pmid:29214842 |
| Fabi A et al. | Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter? | 2017 | Future Oncol | pmid:29182361 |
| Moore KN et al. | A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. | 2018 | Future Oncol | pmid:29098867 |
| Peddi PF and Hurvitz SA | Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer. | 2013 | Future Oncol | pmid:23469968 |
| Chu YW and Polson A | Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia. | 2013 | Future Oncol | pmid:23469971 |
| Bighin C et al. | Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients. | 2013 | Future Oncol | pmid:23837759 |
| Ono Y et al. | Antitumor and cytocidal activities of a newly isolated benzenoid ansamycin, macbecin I. | 1982 | Gan | pmid:6186564 |
| Tsuruo T et al. | Establishment and properties of vincristine-resistant human myelogenous leukemia K562. | 1983 | Gan | pmid:6580255 |
| Yabe N et al. | [A Case of Advanced Breast Cancer in Which Marked Improvement of Joint Pain Was Obtained with Stepwise Dose Reduction of Trastuzumab Emtansine (T-DM1)]. | 2015 | Gan To Kagaku Ryoho | pmid:26805183 |
| Noguchi E and Shimizu C | [T-DM1 and pertuzumab: emerging anti-HER2 therapeutics]. | 2013 | Gan To Kagaku Ryoho | pmid:23306913 |
| Boku N | HER2-positive gastric cancer. | 2014 | Gastric Cancer | pmid:23563986 |
| Coussy F et al. | [New targeted therapies in breast cancer]. | 2014 | Gynecol Obstet Fertil | pmid:25442825 |
| Moore KN et al. | Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. | 2018 | Gynecol. Oncol. | pmid:30093227 |
| Menderes G et al. | Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. | 2017 | Gynecol. Oncol. | pmid:28705408 |
| Menderes G et al. | SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. | 2017 | Gynecol. Oncol. | pmid:28473206 |
| Teplinsky E and Muggia F | Targeting HER2 in ovarian and uterine cancers: challenges and future directions. | 2014 | Gynecol. Oncol. | pmid:25220628 |
| Martin LP et al. | Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. | 2017 | Gynecol. Oncol. | pmid:28843653 |
| Carvajal-Hausdorf DE et al. | Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance. | 2017 | Gynecol. Oncol. | pmid:28196634 |
| Breakthrough breast cancer drug. Finally, some hope for women who've run out of options. | 2012 | Harv Health Lett | pmid:23243689 | |
| Drachman JG and Senter PD | Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer. | 2013 | Hematology Am Soc Hematol Educ Program | pmid:24319196 |
| Yeo W et al. | Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. | 2018 | Hong Kong Med J | pmid:29326401 |
| Damodaran S and Olson EM | Targeting the human epidermal growth factor receptor 2 pathway in breast cancer. | 2012 | Hosp Pract (1995) | pmid:23299030 |
| Watanabe J et al. | Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer. | In Vivo | pmid:28438884 | |
| Madden R et al. | Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
. | 2018 | Int J Clin Pharmacol Ther | pmid:29231164 |
| Janthur WD et al. | Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice. | 2012 | Int J Mol Sci | pmid:23443108 |
| Zhong P et al. | αβ integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo. | 2017 | Int J Nanomedicine | pmid:29138558 |
| Li Y et al. | EpCAM aptamer-functionalized polydopamine-coated mesoporous silica nanoparticles loaded with DM1 for targeted therapy in colorectal cancer. | 2017 | Int J Nanomedicine | pmid:28894364 |
| Mang Y et al. | Efficient elimination of CD103-expressing cells by anti-CD103 antibody drug conjugates in immunocompetent mice. | 2015 | Int. Immunopharmacol. | pmid:25467246 |
| Takegawa N et al. | DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. | 2017 | Int. J. Cancer | pmid:28677116 |
| Ladino CA et al. | Folate-maytansinoids: target-selective drugs of low molecular weight. | 1997 | Int. J. Cancer | pmid:9399666 |
| Kim SB et al. | Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. | 2016 | Int. J. Cancer | pmid:27428671 |
| Yu L et al. | Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model. | 2014 | Int. J. Gynecol. Cancer | pmid:24987913 |
| Sauter A et al. | Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. | 2007 | Int. J. Oncol. | pmid:17332932 |
| Zhang YG et al. | Nocardiopsis ansamitocini sp. nov., a new producer of ansamitocin P-3 of the genus Nocardiopsis. | 2016 | Int. J. Syst. Evol. Microbiol. | pmid:26486850 |
| Shah MH et al. | Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. | 2016 | Invest New Drugs | pmid:26961907 |
| Lapusan S et al. | Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. | 2012 | Invest New Drugs | pmid:21519855 |
| Lieberman P and Castells M | Desensitization to chemotherapeutic agents. | 2014 Jan-Feb | J Allergy Clin Immunol Pract | pmid:24565784 |
| Rebert CS et al. | Effects of vincristine, maytansine, and cis-platinum on behavioral and electrophysiological indices of neurotoxicity in the rat. | 1984 | J Appl Toxicol | pmid:6542922 |
| Sendur MA et al. | Does trastuzumab-emtansine have better cardiac safety profile in contrast to trastuzumab? | 2013 Jul-Sep | J BUON | pmid:24065505 |
| Wang C et al. | Chromatography-based methods for determining molar extinction coefficients of cytotoxic payload drugs and drug antibody ratios of antibody drug conjugates. | 2016 | J Chromatogr A | pmid:27286648 |
| Gupta M et al. | Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. | 2012 | J Clin Pharmacol | pmid:21953571 |
| Zhong P et al. | αβ Integrin-targeted reduction-sensitive micellar mertansine prodrug: Superb drug loading, enhanced stability, and effective inhibition of melanoma growth in vivo. | 2017 | J Control Release | pmid:27986551 |
| Sibaud V et al. | T-DM1 extravasation: first description. | 2016 | J Eur Acad Dermatol Venereol | pmid:25879278 |
| Schönfeld K et al. | Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies. | 2017 | J Hematol Oncol | pmid:28077160 |
| Liu Z et al. | Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry. | 2005 | J Mass Spectrom | pmid:15674857 |
| Parikh A et al. | Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. | 2017 | J Natl Compr Canc Netw | pmid:28040715 |
| Baron JM et al. | Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. | 2015 | J Oncol Pharm Pract | pmid:24682654 |
| Shafaee MN et al. | Skin Necrosis After Ado-Trastuzumab Emtansine Extravasation. | 2017 | J Oncol Pract | pmid:28678590 |
| Mohamed HE et al. | Stability assessment of antibody-drug conjugate Trastuzumab emtansine in comparison to parent monoclonal antibody using orthogonal testing protocol. | 2018 | J Pharm Biomed Anal | pmid:29258046 |
| Liu Y et al. | LC-MS/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1). | 2017 | J Pharm Biomed Anal | pmid:28131055 |
| Iwamoto N et al. | LC-MS bioanalysis of Trastuzumab and released emtansine using nano-surface and molecular-orientation limited (nSMOL) proteolysis and liquid-liquid partition in plasma of Trastuzumab emtansine-treated breast cancer patients. | 2017 | J Pharm Biomed Anal | pmid:28648785 |
| Heudi O et al. | Quantitative analysis of maytansinoid (DM1) in human serum by on-line solid phase extraction coupled with liquid chromatography tandem mass spectrometry - Method validation and its application to clinical samples. | 2016 | J Pharm Biomed Anal | pmid:26771131 |
| Liu Z et al. | An API LC/MS/MS quantitation method for ansamitocin P-3 (AP3) and its preclinical pharmacokinetics. | 2004 | J Pharm Biomed Anal | pmid:15533675 |
| Suchocki JA and Sneden AT | Characterization of decomposition products of maytansine. | 1987 | J Pharm Sci | pmid:11002812 |
| Wiggins B et al. | Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates. | 2015 | J Pharm Sci | pmid:25631158 |
| Lu SX et al. | Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy. | 2005 | J Pharm Sci | pmid:15729708 |
| Gibiansky L and Gibiansky E | Target-mediated drug disposition model and its approximations for antibody-drug conjugates. | 2014 | J Pharmacokinet Pharmacodyn | pmid:24322877 |
| Haddish-Berhane N et al. | On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. | 2013 | J Pharmacokinet Pharmacodyn | pmid:23933716 |
| Jumbe NL et al. | Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. | 2010 | J Pharmacokinet Pharmacodyn | pmid:20424896 |
| Yao Y et al. | Preparative isolation and purification of anti-tumor agent ansamitocin P-3 from fermentation broth of Actinosynnema pretiosum using high-performance counter-current chromatography. | 2010 | J Sep Sci | pmid:20235129 |
| Weiler D et al. | Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer. | 2015 | J Thorac Oncol | pmid:25789838 |
| Chuang JC et al. | ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. | 2017 | J Thorac Oncol | pmid:28167203 |
| Wang HH et al. | Tau overexpression inhibits cell apoptosis with the mechanisms involving multiple viability-related factors. | 2010 | J. Alzheimers Dis. | pmid:20413892 |
| Carroll BJ et al. | Identification of a set of genes involved in the formation of the substrate for the incorporation of the unusual "glycolate" chain extension unit in ansamitocin biosynthesis. | 2002 | J. Am. Chem. Soc. | pmid:11960423 |
| Moss SJ et al. | Identification of asm19 as an acyltransferase attaching the biologically essential ester side chain of ansamitocins using N-desmethyl-4,5-desepoxymaytansinol, not maytansinol, as its substrate. | 2002 | J. Am. Chem. Soc. | pmid:12047169 |
| Taft F et al. | Timing of the Delta(10,12)-Delta(11,13) double bond migration during ansamitocin biosynthesis in Actinosynnema pretiosum. | 2009 | J. Am. Chem. Soc. | pmid:19292483 |
| Spiteller P et al. | The post-polyketide synthase modification steps in the biosynthesis of the antitumor agent ansamitocin by Actinosynnema pretiosum. | 2003 | J. Am. Chem. Soc. | pmid:14624546 |
| Wenzel SC et al. | On the biosynthetic origin of methoxymalonyl-acyl carrier protein, the substrate for incorporation of "glycolate" units into ansamitocin and soraphen A. | 2006 | J. Am. Chem. Soc. | pmid:17076505 |
| Hatano K et al. | Biosynthetic origin of aminobenzenoid nucleus (C7N-unit) of ansamitocin, a group of novel maytansinoid antibiotics. | 1982 | J. Antibiot. | pmid:7174527 |
| Tanida S et al. | Ansamitocin analogs from a mutant strain of Nocardia. I. Isolation of the mutant, fermentation and antimicrobial properties. | 1981 | J. Antibiot. | pmid:7275830 |
| Izawa M et al. | Ansamitocin analogs from a mutant strain of Nocardia. II. Isolation and structure. | 1981 | J. Antibiot. | pmid:7275831 |
| Tanida S et al. | Ansamitocins, maytansinoid antitumor antibiotics. Producing organism, fermentation, and antimicrobial activities. | 1980 | J. Antibiot. | pmid:7380728 |
| Nakahama K et al. | Microbial conversion of ansamitocin. | 1981 | J. Antibiot. | pmid:7333971 |
| Izawa M et al. | Demethylation of ansamitocins and related compounds. | 1981 | J. Antibiot. | pmid:7333972 |
| Izawa M et al. | Hydroxylation of ansamitocin P-3. | 1981 | J. Antibiot. | pmid:7333973 |
| Lu C et al. | A novel amide N-glycoside of ansamitocins from Actinosynnema pretiosum. | 2004 | J. Antibiot. | pmid:15303496 |
| Lin CM and Hamel E | Effects of inhibitors of tubulin polymerization on GTP hydrolysis. | 1981 | J. Biol. Chem. | pmid:6114958 |
| Roach MC and Ludueña RF | Different effects of tubulin ligands on the intrachain cross-linking of beta 1-tubulin. | 1984 | J. Biol. Chem. | pmid:6480599 |
| Bai RL et al. | Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. | 1990 | J. Biol. Chem. | pmid:2211617 |
| Bai RL et al. | Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. | 1991 | J. Biol. Chem. | pmid:1874739 |